Evaluation and follow-up of patients with N1-3 M0 or NXM1 prostate cancer in phase III trials

Urology

Volumn 49, Issue 4 SUPPL., 1997, Pages 39-45

  Hall, Reginald ^a   Hedlund, Per Olov ^b   Ackermann, Rolf ^c   Bruchovsky, Nicholas ^d   Dalesio, Otilia ^e   Debruyne, Frans ^f   Murphy, Gerald P ^g   Parmar, Mahesh K B ^h   Pavone Macaluso, Michele ⁱ   Ruutu, Mirja ^j   Smith, Philip ^k  

^a FREEMAN HOSPITAL   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^h MEDICAL RESEARCH COUNCIL   (United Kingdom)

ⁱ Istituto di Materie Urologiche   (Italy)

^j UNIVERSITY OF HELSINKI   (Finland)

^k ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER STAGING; CANCER SURVIVAL; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

EID: 0030995596     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80322-7     Document Type: Article

References (27)

1. Jones WG, Akaza H, van Oosterom AT, and Kotake T: Objective Response Criteria in Phase II and Phase III Studies. EORTC Genitourinary Monograph 5: Progress and Controversies in Oncological Urology II. New York, Alan R Liss Inc., 1988, pp 243-260.
2. Newling DWW, McLeod D, Soloway M, Di Silverio F, and Smith P: Proceedings of the International Workshop in Prostatic Cancer and Benign Hypertrophy; Panel V Distant Disease. Cancer 70: 365-367, 1992.
3. de Voogt HJ, Suciu S, and Sylvester R, et al: Prognostic Factor Analysis from EORTC Trials in Advance Prostatic Cancer. EORTC Genitourinary Monograph 7: Prostate Cancer and Testicular Cancer. New York, Wiley-Liss Inc., 1990, pp 69-72.
4. Parmar MKB, and Machin D: Survival Analysis, A Practical Approach. New York, John Wiley and Sons, 1995, pp 193-207.
5. Blumenstein BA: Some statistical considerations for the interpretation of trials of combined androgen therapy. Cancer 72(suppl): 3834-3840, 1993.
6. Medical Research Council Prostate Cancer Working Party Investigators Group: Immediate v deferred treatment for advanced prostatic cancer: initial results of the MRC Trial. Br J Urol 79: 235-246, 1997.
7. Crawford ED, Eisenberger MA, and McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424, 1989.
8. Denis LJ, Carnelrode Moura JL, Bono A, et al: Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). Urology 42: 119-130, 1993.
9. EORTC Protocol 30846. Unpublished Data.
10. Schröder FH: Treatment response criteria for prostatic cancer. Prostate 5: 181-191, 1988.
11. Schellhammer P, and Sharifi R et al: A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology 45: 745-751, 1995.
12. Murphy GP, Mahler C, and Ho RCS, et al: Proceedings of the International Workshop on Prostatic Cancer and Hyperplasia: Panel VI, Relapsing Disease. Cancer 70(suppl): 368, 1992.
13. Newling DWW: Parameters of Response and Progression in Prostate Cancer. EORTC Genitourinary Monograph 8: Treatment of Prostatic Cancer - Facts and Controversies. New York, Wiley-Liss Inc., 1990, pp 25-48.
14. Smith PH, Debruyne F, and Armitage TG, et al: The Value of the Bone Scan. EORTC Genitourinary Group Monograph 7: Prostate Cancer and Testicular Cancer. New York, Wiley-Liss Inc., 1990, pp 53-57.
15. Cooper EH, Armitage TG, and the Yorkshire Regional Urological Cancer Research Group: The Biochemial Monitoring of Prostate Cancer. EORTC Genitourinary Monograph 7: Prostate Cancer and Testicular Cancer. New York, Wiley-Liss Inc., 1990, pp 23-27.
16. Smith JA, Lange PH, and Janknegt RA, et al: Serum markers as a predictor of response duration and patient survival after hormone therapy for metastatic carcinoma of the prostate. J Urol (in press).
17. Andriole GL: Serum prostate-specific antigen: expanding its role as a measure of treatment response in patients with prostate cancer. J Clin Oncol 11: 596-597, 1993.
18. Miller JL, Ahmann FR, and Drach GW, et al: The Clinical usefulness of serum prostate-specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147: 956-961, 1992.
19. Kelly WK, Scher HI, and Mazumdar M, et al: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11: 607-615, 1993.
20. Leo ME, Bilhartz DL, Bergstralh EJ, and Oesterling JE: Prostate-specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol 145: 802-806, 1991.
21. Thalmann GN, Sikes RA, and Chang SM, et al: Suramin-induced decrease in prostate-specific antigen expression with no effect on tumour growth in the LNCaP model of human prostate cancer. J Natl Cancer Inst 88: 794-801, 1996.
22. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, and Akakura K: Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45: 839-845, 1995 .
23. Schulz KF, Chalmers I, Hayes RJ, and Altman DG: Empirical evidence of bias; dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273: 408-412, 1995.
24. Simon R, and Wiltes RE: Methodologie guidelines for reports of clinical trials. Cancer Treat Rep 65: 1-2, 1985.
25. Blumenstein BA: Overview analysis issues using combined androgen deprivation overview analysis as an example. Urol Oncol 1: 95-100, 1995.
26. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1: 121-129, 1982.
27. Prostate Cancer Trialists Collaborative Group: Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 346: 265-269, 1995